NeoRx hit with shareholder suit

Article

A class action lawsuit was filed against NeoRx last month, charging the monoclonal antibody developerwith violations of state and federal securities laws. The lawsuitis related to a public stock offering completed by Seattle-basedNeoRx last December.

A class action lawsuit was filed against NeoRx last month, charging the monoclonal antibody developerwith violations of state and federal securities laws. The lawsuitis related to a public stock offering completed by Seattle-basedNeoRx last December.

NeoRx stockholder Murray B. Meld filed the suit May 23 in U.S.District Court in Seattle on behalf of himself and other NeoRxshareholders. The lawsuit charges that NeoRx was aware that amajor shareholder, David Blech, planned to divest his shares inthe company yet did not disclose that information in the offering'sprospectus. Blech sold his NeoRx shares in January and April.

NeoRx denied that it had advance knowledge of Blech's activitiesand will defend itself vigorously, according to chief financialofficer Robert M. Littauer. The lawsuit did not specify a damageclaim.

The impetus for the lawsuit could have come from a sharp declinein NeoRx's stock price after the public offering. NeoRx stockfell from $8.50 a share in January to $3.43 on June 8. The declineappears to be due to the overall softness in biotechnology issues,as well as a decline in stocks held by Blech, who owns an investmentbanking company that came under pressure in April, according toLittauer. NeoRx issued no negative news during that period, hesaid.

Recent Videos
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Related Content
© 2025 MJH Life Sciences

All rights reserved.